Teriparatide
9 NDCs across 6 manufacturers|7 Generic,2 Brand
Teriparatide is used to treat hypoparathyroidism and postmenopausal osteoporosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Nov 26, 2002, and the first generic was approved Nov 16, 2023. In 2024, Medicare Part D spent $479 million on Teriparatide across 149,000 claims for 27,000 beneficiaries.
Teriparatide is available as 9 NDCs from 6 manufacturers (7 generic, 2 brand), with NADAC prices from $479.95 to $1841.27 per ML — the most expensive product costs about 3.8× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
9
7G / 2B
Manufacturers
6
competing in market
Price Spread
$479.95 – $1841.27
per ML
7d Activity
avg -2.3% WoW · of 9 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Eli Lilly and Company manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Parathyroid Hormone Analog class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
6 manufacturers producing TERIPARATIDE(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
FORTEO 560 MCG/2.24 ML PEN INJ | $1841.2749 per ML | +0.01% |
FORTEO 560 MCG/2.24 ML PEN INJ | $1841.2749 per ML | +0.01% |
TERIPARATIDE 560 MCG/2.24 ML PEN | $479.9511 per ML | -3.00% |
TERIPARATIDE 560 MCG/2.24 ML PEN | $479.9511 per ML | -3.00% |
TERIPARATIDE 560 MCG/2.24 ML PEN | $479.9511 per ML | -3.00% |
BONSITY 560 MCG/2.24 ML PEN | $479.9511 per ML | -3.00% |
TERIPARATIDE 560 MCG/2.24 ML PEN | $479.9511 per ML | -3.00% |
TERIPARATIDE 560 MCG/2.24 ML PEN | $479.9511 per ML | -3.00% |
TERIPARATIDE 560 MCG/2.24 ML PEN | $479.9511 per ML | -3.00% |
Frequently Asked Questions
What is Teriparatide used to treat?
Teriparatide is used to treat hypoparathyroidism and postmenopausal osteoporosis, per the National Library of Medicine's MED-RT classification.
When did Teriparatide become available as a generic?
FDA approved the first generic Teriparatide (ANDA) on Nov 16, 2023.
How much does Medicare spend on Teriparatide?
In 2024, Medicare Part D spent $479 million on Teriparatide across 149,000 claims for 27,000 beneficiaries.
How many Teriparatide products are on the market?
The Teriparatide drug market contains 9 NDCs from 6 manufacturers — 7 generic and 2 brand products.
What is the price range for Teriparatide?
NADAC reference prices for Teriparatide range from $479.9511 to $1841.2749 per ML — the most expensive product costs about 3.8× the cheapest.
Is generic Teriparatide cheaper than brand?
The average generic NADAC for Teriparatide is $479.9511 per ML, versus $1841.2749 for brand-labeled products — brand versions average about 3.8× the generic price.
Which manufacturers make Teriparatide?
6 manufacturers list Teriparatide in NADAC. Ranked by number of NDCs, the largest are Eli Lilly and Company (2), Alvogen Inc. (2), Prasco Laboratories (2), Teva Pharmaceuticals USA Inc. (1), Amphastar Pharmaceuticals, Inc. (1).
How has the price of Teriparatide changed recently?
Over the past 7 days, 2 Teriparatide NDCs rose and 7 fell, with a market-wide average change of -2.3%.